ROKIT Healthcare Inc. (376900.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
17,390.00 KRW
Market cap
268.06 bn KRW
P/E (2025)
–
P/S (2025)
10.21
Dividend yield
0.00 %
Net margin
-10.84 %
Return on equity (ROE)
-24.61 %
Return on assets (ROA)
-5.17 %

ROKIT Healthcare Inc. financials

Fiscal year20242025
Revenue13.11 bn KRW26.25 bn KRW
Gross profit5.98 bn KRW15.69 bn KRW
Operating income-5.57 bn KRW452.88 m KRW
EBIT-491.78 m KRW2.65 bn KRW
Net income-7.65 bn KRW-2.85 bn KRW
Diluted EPS – continuing operations-953.60 KRW-184.58 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About ROKIT Healthcare Inc.

ROKIT Healthcare Inc., a biotechnology company, provides hyper-personalized organ regenerative healthcare solutions in South Korea. The company offers skin regeneration therapy for the treatment of diabetic foot ulcers; cartilage regeneration delivers hyper-personalized therapeutic solutions for osteoarthritis patients; and kidney regeneration, a hyper-personalized treatment for chronic kidney disease (CKD). It also provides bioprinters; bioinks; Huma Media, a human adult stem cell culture media; HumaTein, a human cell-derived whole extracellular matrix; EpiTem, a reconstructed human epidermis model; and anti-aging supplements, as well as operates a tissue bank. The company was formerly known as ROKIT Inc. and changed its name to ROKIT Healthcare Inc. in 2018. The company was incorporated in 2012 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.